Rotenone as a Precision Probe: Unraveling Complex I Dysfunction and Metabolic Regulation

Introduction

Mitochondrial dysfunction underpins a spectrum of human diseases, ranging from neurodegenerative disorders to metabolic syndromes. Among the array of chemical tools available, Rotenone (CAS 83-79-4) stands out as a gold-standard mitochondrial Complex I inhibitor. Widely recognized for its utility in modeling Parkinson's disease and dissecting the intricate web of mitochondrial signaling pathways, Rotenone’s impact is considerably deeper than what conventional overviews suggest. This article probes Rotenone’s advanced applications as a mitochondrial dysfunction inducer, focusing on its capacity to dissect metabolic regulation, proteostasis dynamics, and post-translational modifications, while bridging foundational mechanisms with cutting-edge research on mitochondrial enzyme turnover and signaling.

The Unique Mechanistic Profile of Rotenone

Inhibiting Mitochondrial Complex I with Precision

Rotenone’s primary mode of action is its potent inhibition of NADH:ubiquinone oxidoreductase (Complex I) within the mitochondrial electron transport chain, with an IC₅₀ of 1.7–2.2 μM. By blocking electron transfer, Rotenone disrupts the mitochondrial proton gradient, leading to impaired oxidative phosphorylation. This not only diminishes ATP synthesis but also triggers the accumulation of NADH and the generation of reactive oxygen species (ROS). The subsequent ROS-mediated cell death is central to studies of neurodegenerative disease mechanisms and mitochondrial stress (Wang et al., 2025).

From ROS Generation to Cellular Fate Decisions

Disruption of Complex I by Rotenone results in elevated ROS, which serve as signaling molecules that can tip the balance between cell survival and death. In differentiated SH-SY5Y neuroblastoma cells, Rotenone acts as a powerful apoptosis inducer, reducing mitochondrial movement and revealing a distinctive biphasic survival curve at nanomolar concentrations over prolonged exposure. Beyond apoptosis, Rotenone’s impact on autophagy pathway research, caspase activation assays, and stress-responsive MAP kinase pathways—including p38 MAPK and JNK—is well-established, providing a versatile platform for dissecting both canonical and non-canonical cell death and survival mechanisms.

Advanced Insights: Rotenone, Mitochondrial Proteostasis, and Metabolic Regulation

Beyond Canonical Inhibition: Post-Translational Regulation and Enzyme Turnover

While many existing articles emphasize Rotenone’s role in electron transport disruption and ROS-mediated cell death, this article expands the discussion to the emerging interface of mitochondrial proteostasis and metabolic regulation. Recent research (Wang et al., 2025) has elucidated how mitochondrial DNAJC co-chaperones—specifically TCAIM—selectively bind and degrade key TCA cycle enzymes like a-ketoglutarate dehydrogenase (OGDH), reshaping mitochondrial metabolism. This introduces a layer of post-translational control that operates independently of direct Complex I inhibition.

Rotenone-induced mitochondrial stress can be leveraged to study how modulation of proteostasis components (such as HSPA9 and LONP1) influences enzyme turnover and metabolic flux. By combining Rotenone exposure with genetic or pharmacological manipulation of these proteostasis regulators, researchers gain unprecedented resolution in deciphering the interplay between electron transport, ROS signaling, and TCA cycle regulation—an approach that goes beyond the foundational perspectives offered in existing guides on mitochondrial proteostasis. While those resources provide a broad overview, this article uniquely contextualizes Rotenone within the framework of post-translational enzyme regulation and metabolic adaptation.

Case Study: Rotenone for Modeling Proteostatic Stress in Neurodegeneration

In neurodegenerative disease research, mitochondrial dysfunction is a double-edged sword—acting both as a cause and consequence of proteostatic imbalance. Rotenone’s established utility in Parkinson's disease models, particularly via intranasal administration in animal studies, allows for precise induction of dopaminergic neurite degeneration and olfactory deficits. However, by integrating insights from the TCAIM-OGDH axis, researchers can now interrogate how mitochondrial chaperone systems respond to acute Complex I inhibition. For instance, coupling Rotenone treatment with analysis of OGDH levels and activity provides a powerful readout for mitochondrial protein quality control and its downstream effects on cellular metabolism.

Comparative Analysis: Rotenone Versus Alternative Mitochondrial Dysfunction Inducers

Alternative Complex I inhibitors (e.g., piericidin A, rotenoids) and agents that disrupt other electron transport chain complexes (such as antimycin A or oligomycin) are frequently employed in mitochondrial research. However, Rotenone’s selectivity, solubility profile (insoluble in ethanol and water, readily soluble in DMSO at ≥77.6 mg/mL), and well-characterized pharmacokinetics make it the preferred choice for reproducible induction of mitochondrial dysfunction—particularly in cell-based assays and animal models requiring precise dose-response control.

Moreover, Rotenone’s capacity to induce both apoptotic and autophagic responses, as well as to activate caspase pathways and stress kinases (p38 MAPK, JNK), distinguishes it from compounds that elicit more restricted or less predictable cellular phenotypes. This versatility is highlighted in previous reviews (e.g., Probing Mitochondrial Complex I and Metabolic Regulation), which catalog Rotenone’s broad research utility. Here, we emphasize how combining Rotenone with emerging tools for manipulating mitochondrial proteostasis (e.g., DNAJC family co-chaperones) opens new avenues for dissecting disease-relevant metabolic rewiring.

Rotenone in Advanced Neurodegenerative Disease Research

Dissecting Pathways in Parkinson’s Disease Models

Rotenone’s reputation as a tool for Parkinson’s disease modeling stems from its ability to induce selective degeneration of substantia nigra dopaminergic neurons—a hallmark of the human disorder. Recent advances extend this model by incorporating assays for mitochondrial proteostasis, autophagy flux, and ROS-mediated cell death, allowing for nuanced exploration of disease etiology. For example, Rotenone-driven caspase activation assays and measurements of p38 MAPK/JNK signaling in SH-SY5Y cells or primary neuronal cultures provide mechanistic clarity regarding how mitochondrial stress translates into cell fate decisions.

Crucially, these models now benefit from integrating the latest insights into post-translational regulation of mitochondrial enzymes. By monitoring OGDH turnover in response to Rotenone, researchers can assess how mitochondrial protein quality control mechanisms intersect with metabolic signaling—an approach not addressed in prior overviews such as Rotenone: A Precision Tool for Dissecting Mitochondrial Metabolism. While that article underscores targeted interrogation of metabolism, our focus on enzyme degradation and proteostasis adds a new dimension to the paradigm.

Expanding to Other Neurodegenerative and Metabolic Models

Beyond Parkinson’s disease, Rotenone’s utility extends to models of Alzheimer’s disease, amyotrophic lateral sclerosis, and metabolic syndrome. By leveraging its dual role as a mitochondrial dysfunction inducer and a probe for protein turnover, researchers can interrogate cross-talk between mitochondrial ROS, unfolded protein response, and metabolic flux. This is particularly relevant in contexts where mitochondrial enzyme abundance is dynamically regulated—an area illuminated by the recent demonstration of TCAIM-dependent OGDH degradation (Wang et al., 2025).

Practical Considerations and Product Handling

Effective use of Rotenone requires attention to its physicochemical properties. The compound is a solid at room temperature, insoluble in ethanol and water, but dissolves efficiently in DMSO at high concentrations (≥77.6 mg/mL). Stock solutions should be prepared fresh, stored below -20°C, and not kept for extended periods once dissolved to prevent degradation and loss of activity. Rotenone is shipped on blue ice to maintain stability, underscoring its suitability for sensitive research applications.

For detailed protocols and troubleshooting tips, readers are encouraged to consult prior resources such as Advanced Insights into Mitochondrial Dysfunction, which provides comprehensive guidance on experiment setup. Our present analysis, in contrast, focuses on integrating Rotenone into next-generation studies of proteostasis and metabolic regulation, highlighting its role as a linchpin for advanced mitochondrial research.

Conclusion and Future Outlook

Rotenone’s established role as a mitochondrial Complex I inhibitor is only the beginning. By uniting classical applications with emerging insights into proteostasis and post-translational regulation, Rotenone empowers researchers to tackle longstanding questions in neurodegenerative disease and metabolic adaptation. The synergy between chemical inhibition, mitochondrial chaperone systems, and metabolic enzyme turnover defines a new frontier for mitochondrial research.

Future work will undoubtedly expand on the interplay between mitochondrial dysfunction, protein quality control, and cellular metabolism—areas ripe for exploration using Rotenone as a precision probe. By situating Rotenone at the nexus of these disciplines, this article offers a roadmap for the next generation of mitochondrial research, building upon and transcending the foundations laid by previous studies.